These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33101358)

  • 1. Alternative Splicing Events and Splicing Factors Are Prognostic in Adrenocortical Carcinoma.
    Lv J; He Y; Li L; Wang Z
    Front Genet; 2020; 11():918. PubMed ID: 33101358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of survival-associated alternative splicing events and signatures in adrenocortical carcinoma based on TCGA SpliceSeq data.
    Xu N; Ke ZB; Lin XD; Lin F; Chen SH; Wu YP; Chen YH; Wei Y; Zheng QS
    Aging (Albany NY); 2020 Mar; 12(6):4996-5009. PubMed ID: 32217810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of predictive and prognostic alternative splicing signatures in lung adenocarcinoma using machine learning methods.
    Cai Q; He B; Zhang P; Zhao Z; Peng X; Zhang Y; Xie H; Wang X
    J Transl Med; 2020 Dec; 18(1):463. PubMed ID: 33287830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic analysis and prediction model construction of alternative splicing events in hepatocellular carcinoma: a study on the basis of large-scale spliceseq data from The Cancer Genome Atlas.
    Yang L; He Y; Zhang Z; Wang W
    PeerJ; 2019; 7():e8245. PubMed ID: 31844595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma.
    Zhang S; Wu X; Diao P; Wang C; Wang D; Li S; Wang Y; Cheng J
    J Cell Physiol; 2020 May; 235(5):4804-4813. PubMed ID: 31637730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.
    Liu Y; Jia W; Li J; Zhu H; Yu J
    Front Oncol; 2020; 10():587343. PubMed ID: 33117720
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization of alternative splicing events and prognostic signatures in breast cancer.
    Han P; Zhu J; Feng G; Wang Z; Ding Y
    BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Prognostic and Metastatic Alternative Splicing Signatures in Kidney Renal Clear Cell Carcinoma.
    Meng T; Huang R; Zeng Z; Huang Z; Yin H; Jiao C; Yan P; Hu P; Zhu X; Li Z; Song D; Zhang J; Cheng L
    Front Bioeng Biotechnol; 2019; 7():270. PubMed ID: 31681747
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic Signatures of Alternative Splicing Events in Esophageal Carcinoma Based on TCGA Splice-Seq Data.
    Ye P; Yang Y; Zhang L; Zheng G
    Front Oncol; 2021; 11():658262. PubMed ID: 34676158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing.
    Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y
    Front Genet; 2020; 11():534. PubMed ID: 32595697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
    Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
    J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole Genome Analysis and Prognostic Model Construction Based on Alternative Splicing Events in Endometrial Cancer.
    Wang C; Zheng M; Wang S; Nie X; Guo Q; Gao L; Li X; Qi Y; Liu J; Lin B
    Biomed Res Int; 2019; 2019():2686875. PubMed ID: 31355251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel prognostic alternative splicing signature in papillary renal cell carcinoma.
    Duan Y; Zhang D
    J Cell Biochem; 2020 Jan; 121(1):672-689. PubMed ID: 31407370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.
    Zhang D; Zou D; Deng Y; Yang L
    J Ovarian Res; 2021 Sep; 14(1):120. PubMed ID: 34526089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Prognostic Index Based on Alternative Splicing in Papillary Renal Cell Carcinoma.
    Wu Z; Liu J; Sun R; Chen D; Wang K; Cao C; Xu X
    Front Genet; 2019; 10():1333. PubMed ID: 32063918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Alternative mRNA Splicing in Adrenocortical Carcinoma.
    Liang W; Sun F
    Front Endocrinol (Lausanne); 2021; 12():538364. PubMed ID: 33776902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of drug targets and prognosis projection for uterine carcinosarcoma based on alternative splicing events.
    Zhang X; Yin X; Zhang L; Ye Z; Liang G
    Comput Biol Med; 2023 Jan; 152():106346. PubMed ID: 36470146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas.
    Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G
    J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an alternative splicing signature as an independent factor in colon cancer.
    Chen H; Luo J; Guo J
    BMC Cancer; 2020 Sep; 20(1):904. PubMed ID: 32962686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.